Overexpression of insulin‐like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild‐type SDHB‐negative gastrointestinal stromal tumors

Approximately 15% of gastrointestinal stromal tumors (GISTs) in adults and 85% in children lack mutations in KIT and PDGFRA and are known as wild‐type GISTs. Wild‐type GISTs from adults and children express high levels of insulin‐like growth factor 1 receptor (IGF1R) and exhibit stable genomes compared to mutant GISTs. Pediatric wild‐type GISTs, GISTs from the multitumor Carney–Stratakis syndrome, and the Carney triad share other clinicopathological properties (e.g., early‐onset, multifocal GISTs with epitheliod cell morphology), suggesting a common etiology. Carney–Stratakis is an inherited association of GIST and paragangliomas caused by germline mutations in succinate dehydrogenase (SDH) genes. The connection between defective cellular respiration and GIST pathology has been strengthened by the utilization of SDHB immunohistochemistry to identify SDH deficiency in pediatric GISTs, syndromic GISTs, and some adult wild‐type GISTs. SDHB and IGF1R expression was examined in 12 wild‐type and 12 mutant GIST cases. Wild‐type GISTs were screened for coding‐region alterations in SDH genes and for chromosomal aberrations using genome‐wide single‐nucleotide polymorphism and MIP arrays. SDHB‐deficiency, identified in 11/12 wild‐type GIST cases, was tightly associated with overexpression of IGF1R protein and transcript. Biallelic inactivation of the SDHA gene was a surprisingly frequent event, identified in 5 of 11 SDHB‐negative cases, generally due to germline point mutations accompanied by somatic SDHA allelic losses. As a novel finding, inactivation of the SDHC gene from a combination of a heterozygous coding‐region mutation and hypermethylation of the wild‐type allele was found in one SDHB‐negative case. © 2012 Wiley Periodicals, Inc.

[1]  J. Schiffman,et al.  Molecular inversion probes: a novel microarray technology and its application in cancer research. , 2012, Cancer genetics.

[2]  Kevin B. Jones,et al.  Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma. , 2012, Cancer genetics.

[3]  A. Chou,et al.  Succinate dehydrogenase-deficient GISTs are characterized by IGF1R overexpression , 2012, Modern Pathology.

[4]  A. D. Dei Tos,et al.  Differential expression of neural markers in KIT and PDGFRA wild‐type gastrointestinal stromal tumours , 2011, Histopathology.

[5]  P. Rutkowski,et al.  Succinate Dehydrogenase-Deficient GISTs: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 66 Gastric GISTs With Predilection to Young Age , 2011, The American journal of surgical pathology.

[6]  A. Astolfi,et al.  A distinct pediatric-type gastrointestinal stromal tumor in adults: potential role of succinate dehydrogenase subunit A mutations. , 2011, The American journal of surgical pathology.

[7]  W. Sanger,et al.  Genome wide copy number analysis of paediatric Burkitt lymphoma using formalin‐fixed tissues reveals a subset with gain of chromosome 13q and corresponding miRNA over expression , 2011, British journal of haematology.

[8]  R. Casadio,et al.  SDHA loss-of-function mutations in KIT-PDGFRA wild-type gastrointestinal stromal tumors identified by massively parallel sequencing. , 2011, Journal of the National Cancer Institute.

[9]  C. Antonescu,et al.  Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations , 2010, Proceedings of the National Academy of Sciences.

[10]  M. Heinrich,et al.  A molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy number , 2010, Laboratory Investigation.

[11]  P. Bénit,et al.  SDHA is a tumor suppressor gene causing paraganglioma. , 2010, Human molecular genetics.

[12]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[13]  A. Chou,et al.  Immunohistochemistry for SDHB Divides Gastrointestinal Stromal Tumors (GISTs) into 2 Distinct Types , 2010, The American journal of surgical pathology.

[14]  Hanlee P. Ji,et al.  Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. , 2010, Cancer research.

[15]  W. Young,et al.  Gastric Stromal Tumors in Carney Triad Are Different Clinically, Pathologically, and Behaviorally From Sporadic Gastric Gastrointestinal Stromal Tumors: Findings in 104 Cases , 2010, The American journal of surgical pathology.

[16]  A. Godwin,et al.  High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumors , 2009, Genes, chromosomes & cancer.

[17]  S. Fox,et al.  No evidence for promoter region methylation of the succinate dehydrogenase and fumarate hydratase tumour suppressor genes in breast cancer. , 2009 .

[18]  E. Capriotti,et al.  Functional annotations improve the predictive score of human disease‐related mutations in proteins , 2009, Human mutation.

[19]  T. Pajak,et al.  Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor , 2009, Molecular Cancer Therapeutics.

[20]  Hanlee P. Ji,et al.  Molecular inversion probes reveal patterns of 9p21 deletion and copy number aberrations in childhood leukemia. , 2009, Cancer genetics and cytogenetics.

[21]  A. D. Van den Abbeele,et al.  Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib , 2009, Pediatric blood & cancer.

[22]  A. Hartmann,et al.  V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours , 2009, Journal of Clinical Pathology.

[23]  P. Spellman,et al.  High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays , 2009, BMC Medical Genomics.

[24]  K. Owzar,et al.  Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Narasimhan P. Agaram,et al.  Novel V600E BRAF mutations in imatinib‐naive and imatinib‐resistant gastrointestinal stromal tumors , 2008, Genes, chromosomes & cancer.

[26]  A. Godwin,et al.  The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors , 2008, Cell cycle.

[27]  D. Flieder,et al.  Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors , 2008, Proceedings of the National Academy of Sciences.

[28]  Narasimhan P. Agaram,et al.  Molecular Characterization of Pediatric Gastrointestinal Stromal Tumors , 2008, Clinical Cancer Research.

[29]  James Ireland,et al.  Analysis of molecular inversion probe performance for allele copy number determination , 2007, Genome Biology.

[30]  A. Sparks,et al.  The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.

[31]  J. Fletcher,et al.  Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. , 2007, Cancer research.

[32]  C. Stratakis,et al.  Familial gastrointestinal stromal tumors and germ-line mutations. , 2007, The New England journal of medicine.

[33]  E. Campo,et al.  Genetics of carney triad: recurrent losses at chromosome 1 but lack of germline mutations in genes associated with paragangliomas and gastrointestinal stromal tumors. , 2007, The Journal of clinical endocrinology and metabolism.

[34]  I. Hassinen,et al.  Inhibition of Hypoxia-inducible Factor (HIF) Hydroxylases by Citric Acid Cycle Intermediates , 2007, Journal of Biological Chemistry.

[35]  E. Gottlieb,et al.  Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer , 2006, Oncogene.

[36]  J. Blay,et al.  KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. , 2006, European journal of cancer.

[37]  Ronald W. Davis,et al.  Allele quantification using molecular inversion probes (MIP) , 2005, Nucleic acids research.

[38]  Sandro Santagata,et al.  A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas , 2005, PLoS genetics.

[39]  Adrian A Canutescu,et al.  Analysis of KIT Mutations in Sporadic and Familial Gastrointestinal Stromal Tumors: Therapeutic Implications through Protein Modeling , 2005, Clinical Cancer Research.

[40]  N. Socci,et al.  Gastrointestinal Stromal Tumors in Children and Young Adults: A Clinicopathologic, Molecular, and Genomic Study of 15 Cases and Review of the Literature , 2005, Journal of pediatric hematology/oncology.

[41]  J. Fletcher,et al.  KIT-Negative Gastrointestinal Stromal Tumors: Proof of Concept and Therapeutic Implications , 2004, The American journal of surgical pathology.

[42]  S. Antonarakis,et al.  Mutation Nomenclature , 2003, Current protocols in human genetics.

[43]  Long-Cheng Li,et al.  MethPrimer: designing primers for methylation PCRs , 2002, Bioinform..

[44]  C. J. Chen,et al.  KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. , 2001, Cancer research.

[45]  S. Antonarakis,et al.  Mutation nomenclature extensions and suggestions to describe complex mutations: A discussion , 2000 .

[46]  J. Carney,et al.  Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence. , 1999, Mayo Clinic proceedings.

[47]  K. Chorneyko,et al.  Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. , 1999, The American journal of surgical pathology.

[48]  L. Kindblom,et al.  Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. , 1998, The American journal of pathology.

[49]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[50]  S. Sheps,et al.  The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondroma. , 1977, The New England journal of medicine.

[51]  M. O'sullivan,et al.  SDHB immunohistochemistry: a useful tool in the diagnosis of Carney–Stratakis and Carney triad gastrointestinal stromal tumors , 2011, Modern Pathology.

[52]  Jean-Yves Scoazec,et al.  BRAF mutation status in gastrointestinal stromal tumors. , 2010, American journal of clinical pathology.

[53]  Hanlee P. Ji,et al.  Molecular inversion probe assay for allelic quantitation. , 2009, Methods in molecular biology.

[54]  J. Ellison,et al.  Clinical and molecular genetics of patients with the Carney–Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD , 2008, European Journal of Human Genetics.

[55]  Mostafa Ronaghi,et al.  Molecular inversion probe assay. , 2007, Methods in molecular biology.

[56]  S Rozen,et al.  Primer3 on the WWW for general users and for biologist programmers. , 2000, Methods in molecular biology.

[57]  M. Waters,et al.  of Insulin-Like Growth , 1993 .

[58]  M. Heinrich,et al.  Insulin‐like growth factor 1 receptor expression in wild‐type GISTs: A potential novel therapeutic target , 2009, International journal of cancer.